Testing Depemokimab — an investigational long-acting anti–IL-5 therapy — to reduce exacerbations in adults with moderate-to-severe COPD.
The screening call takes about 5 minutes. Coordinators will walk you through the full eligibility criteria; the items below are the most common gates.
The fastest path is to submit the pre-qualification form on this page or call the enrollment line at 386-218-5911. A study coordinator will review your information and call you within one business day to schedule a free screening visit.
You are never obligated to continue. You can stop at any step — before signing consent, during screening, or at any point after enrollment.
This study is conducted at Optimal Research Sites, an independent clinical trial facility in Orange City, Florida. We've conducted Phase I–IV trials since 1994, with a dedicated 9-bed Phase I inpatient unit, certified sample processing laboratory, and a bilingual study team. Every trial runs under IRB oversight and ICH Good Clinical Practice standards.
Evaluating a new investigational therapy for adults with Type 2 Diabetes and obesity — measuring weight loss, metabolic health, and glycemic control.
See study →Evaluating Depemokimab to reduce asthma attacks and improve daily control in adults with severe, uncontrolled asthma.
See study →Evaluating Vosoritide, an investigational therapy designed to support bone growth and improve height outcomes in children with Idiopathic Short Stature.
See study →